University Health Network
University Health Network
Toronto, Ontario, Canada52 results · Page 1 of 3
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, alveolar soft part sarcoma, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, myomatous neoplasm, neoplasm, renal cell carcinoma, sarcoma, skin disorder, triple-negative breast carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-10-08 | NCT07297667 | |
| CfDNA in Hereditary And High-risk Malignancies 2 | Adnexal Diseases, Colorectal Neoplasms, Hereditary Nonpolyposis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Li-Fraumeni syndrome, Neoplasms by Site, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gonadal disorder, hereditary breast ovarian cancer syndrome, hereditary disease, hereditary neoplastic syndrome, intestinal disorder, malignant endocrine neoplasm, metabolic disease, neoplasm, ovarian cancer, ovarian disorder, skin disorder, stomach disorder | Recruiting | Not stated | 2026-10-08 | NCT06726642 | |
| PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation | cardiovascular disorder, hypertensive disorder, lung disorder, pulmonary hypertension, respiratory system disorder, vascular disorder | Recruiting | Not applicable | 2026-10-05 | NCT04901884 | |
| Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD) | cGVHD | Not yet recruiting | Phase 2 | 2026-10-02 | NCT07643025 | |
| A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | neoplasm | Active, not recruiting | Phase 1 | 2026-09-25 | NCT04606381 | |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2026-09-24 | NCT05640999 | |
| Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm | Recruiting | Phase 2 | 2026-09-17 | NCT07341191 | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2026-09-17 | NCT04910568 | |
| Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-09-17 | NCT02436707 | |
| CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2026-09-16 | NCT03624543 | |
| Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Site, neoplasm | Recruiting | Phase 3 | 2026-09-15 | NCT06641791 | |
| LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT06623461 | |
| Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, non-Hodgkin lymphoma | Recruiting | Phase 2 | 2026-09-15 | NCT05998642 | |
| Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia | acute leukemia | Recruiting | Not applicable | 2026-09-15 | NCT04224974 | |
| A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies | cancer, neoplasm | Recruiting | Phase 2 | 2026-09-15 | NCT03847649 | |
| Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC | Lung Cancer Metastatic | Active, not recruiting | Phase 2 | 2026-09-01 | NCT03057106 | |
| STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2026-08-11 | NCT06880523 | |
| Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 3 | 2026-08-11 | NCT06391242 | |
| STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision | vulvar squamous cell carcinoma | Recruiting | Not applicable | 2026-08-11 | NCT06358469 | |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma | gastroesophageal adenocarcinoma | Recruiting | Phase 2 | 2026-08-11 | NCT06043427 | |
| Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2026-07-31 | NCT04093167 | |
| Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Recruiting | Phase 2 | 2026-07-21 | NCT04918186 | |
| Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cell Transplant: A Pilot Study | Lymphoma Receiving CAR-T Therapy | Recruiting | Not applicable | 2026-07-08 | NCT07509450 | |
| Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 3 | 2026-06-29 | NCT03173248 | |
| Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Early phase 1 | 2026-06-24 | NCT04161248 |